|
2025
|
G/S
|
Pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, au... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer;
pharmaceutical preparations for the tre... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea... |
|
2024
|
G/S
|
Pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutica... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of skeletal or
chondrocyte disorders; pharmaceutic... |
|
|
G/S
|
Pharmaceutical preparations for the prevention and treatment of cancer. Providing a website to pa... |
|
|
Invention
|
Sustained-release dosage forms of ruxolitinib.
The present invention relates to sustained-releas... |
|
|
Invention
|
Sustained release dosage forms for a jak1 inhibitor.
This invention relates to sustained release... |
|
|
G/S
|
pharmaceutical preparations for the treatment of fibrotic disorders; pharmaceutical preparations ... |
|
|
G/S
|
pharmaceutical preparations for the treatment of hypophosphatemia disorders; pharmaceutical prepa... |
|
|
G/S
|
pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparat... |
|
|
G/S
|
pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutica... |
|
|
G/S
|
pharmaceutical preparations for the treatment of myeloproliferative disorders; Pharmaceutical pre... |
|
|
G/S
|
pharmaceutical preparations for the treatment of graft versus host disorder (GVHD); pharmaceutica... |
|
|
G/S
|
pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparat... |
|
|
G/S
|
Préparations pharmaceutiques; préparations pharmaceutiques pour le traitement du cancer; préparat... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of cancer; pharmaceut... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of dermatological disorders.
Printed publications, ... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of
dermatological disorders. Printed publications,... |
|
|
G/S
|
Downloadable software for tracking medical conditions and treatments Printed publications, namely... |
|
|
Invention
|
Salts and processes of preparing a pi3k inhibitor.
The present application provides processes fo... |
|
|
Invention
|
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors.
This application relates to... |
|
|
G/S
|
Printed publications, namely, brochures, newsletters, and pamphlets relating to medical issues, p... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of oncological disorders; pharmaceutical preparatio... |
|
|
Invention
|
Topical formulation for a jak inhibitor. This invention relates to pharmaceutical formulations fo... |
|
|
Invention
|
Bipyrazole derivatives as jak inhibitors. The present invention provides compounds of Formula I:
... |
|
2023
|
G/S
|
Pharmaceutical preparations for the treatment of dermatological disorders Printed publications, n... |
|
|
Invention
|
Tricyclic fused thiophene derivatives as jak inhibitors.
The present invention provides tricycli... |
|
|
G/S
|
Financial assistance qualification for co-pay assistance; reimbursement navigation; coverage bene... |
|
|
Invention
|
Substituted tricyclic compounds as fgfr inhibitors.
The present invention relates to tricyclic c... |
|
|
Invention
|
Heterocyclylamines as pi3k inhibitors. The present invention provides heterocyclylamine derivativ... |
|
|
Invention
|
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase.
The present invention is direct... |
|
|
Invention
|
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c] pyridin-7(6h)-ones as inhibitors of bet p... |
|
2022
|
Invention
|
Sustained-release dosage forms of ruxolitinib. The present invention relates to sustained-release... |
|
|
Invention
|
Topical formulation for a jak inhibitor.
This invention relates to pharmaceutical formulations f... |
|
|
Invention
|
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzami... |
|
|
Invention
|
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhi... |
|
|
Invention
|
Piperidin-4-yl azetidine derivatives as jak1 inhibitors.
The present invention provides piperidi... |
|
|
Invention
|
Imidazotriazines and imidazopyrimidines as kinase inhibitors. The present invention is directed t... |
|
2021
|
Invention
|
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3... |
|
|
Invention
|
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors. This application relates to ... |
|
|
Invention
|
Tricyclic fused thiophene derivatives as jak inhibitors. The present invention provides tricyclic... |
|
|
Invention
|
Salts and processes of preparing a pi3k inhibitor. The present application provides processes for... |
|
|
Invention
|
Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders.
The pre... |
|
|
Invention
|
Use of pyrazolopyrimidine derivatives for the treatment of pi3k-δ related disorders. The present ... |
|
|
Invention
|
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet pr... |
|
|
Invention
|
Substituted tricyclic compounds as fgfr inhibitors. The present invention relates to tricyclic co... |
|
|
Invention
|
Sustained release dosage forms for a jak1 inhibitor. This invention relates to sustained release ... |
|
|
Invention
|
Bicyclic heterocycles as fgfr4 inhibitors. The present invention relates to bicyclic heterocycles... |
|
|
Invention
|
Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3... |
|
|
Invention
|
Bicyclic heterocycles as fgfr inhibitors. The present invention relates to bicyclic heterocycles,... |
|
2020
|
Invention
|
Tricyclic heterocycles as bet protein inhibitors. The present invention relates to tricyclic hete... |
|
|
Invention
|
Pyrimidinones as pi3k inhibitors. The present invention provides pyrimidinones that modulate the ... |
|
|
Invention
|
Salts of an lsd1 inhibitor. The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl... |
|
|
Invention
|
Cyclopropylamines as lsd1 inhibitors. The present invention is directed to cyclopropylamine deriv... |
|
|
Invention
|
Treatment of b-cell malignancies by a combination jak and pi3k inhibitors.
This invention relate... |
|
|
Invention
|
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase. The present invention is directed... |
|
|
Invention
|
Jak1 inhibitors for the treatment of myelodysplastic syndromes.
This invention relates to JAK1 s... |
